• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

SCH-1473759

CAS No. 1094069-99-4

SCH-1473759 ( SCH1473759 | SCH 1473759 )

产品货号. M10365 CAS No. 1094069-99-4

Aurora A 和 B 的有效皮摩尔双重抑制剂,IC50 分别为 0.02 和 0.03 nM;显示出改善的细胞效力(phos-HH3 抑制 IC50=25 nM)和固有水溶性(11.4 mM)。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥1774 有现货
50MG ¥6051 有现货
100MG ¥9234 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    SCH-1473759
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Aurora A 和 B 的有效皮摩尔双重抑制剂,IC50 分别为 0.02 和 0.03 nM;显示出改善的细胞效力(phos-HH3 抑制 IC50=25 nM)和固有水溶性(11.4 mM)。
  • 产品描述
    A potent, picomolar, dual inhibitor of Aurora A and B with IC50 of 0.02 and 0.03 nM, respectively; shows improved cell potency (phos-HH3 inhibition IC50=25 nM) and intrinsic aqueous solubility (11.4 mM); emonstrated efficacy and target engagement in human tumor xenograft mouse models.
  • 体外实验
    SCH-1473759 directly binds to aurora A and B with Kds of 20 and 30 nM, respectively. SCH-1473759 also inhibits the Src family of kinases (IC50<10 nM), Chk1 (IC50=13 nM), VEGFR2 (IC50=1 nM), and IRAK4 (IC50=37 nM). It does not have significant activity (IC50>1000 nM) against 34 other kinases representing different families of the kinome. SCH-1473759 inhibits HCT116 cells proliferation with an IC50 of 6 nM. SCH 1473759 inhibits tumor cell lines from different tissues (breast, ovarian, prostate, lung, colon, brain, gastric, renal, skin, and leukemia). The most sensitive cell lines includ A2780, LNCap, N87, Molt4, K562, and CCRF-CEM with IC50 values <5 nM.
  • 体内实验
    SCH-1473759 at a low dose of 5 mg/kg (ip, bid) is well-tolerated in a continuous dosing schedule and shows 50% tumor growth inhibition(TGI) on day 16. A higher dose of 10mg/kg(ip, bid) is well-tolerated in an intermittent schedule (5 days on, 5 days off) and gave 69% TGI on day 16. SCH-1473759 shows good exposure in all species with the clearance being high in rodents and moderate in dog and monkey. The half-life is also moderate, but the tissue distribution is high. SCH 1473759 dose- and schedule-dependent anti-tumor activity in four human tumor xenograft models. Further, the efficacy is enhanced in combination with taxanes and found to be most efficacious when SCH 1473759 is dosed 12-h post-taxane treatment.
  • 同义词
    SCH1473759 | SCH 1473759
  • 通路
    Cell Cycle/DNA Damage
  • 靶点
    Aurora Kinase
  • 受体
    Aurora Kinase
  • 研究领域
    Cancer
  • 适应症
    ——

化学信息

  • CAS Number
    1094069-99-4
  • 分子量
    426.5385
  • 分子式
    C20H26N8OS
  • 纯度
    >98% (HPLC)
  • 溶解度
    10 mM in DMSO
  • SMILES
    CC(C)(N(CC)CC1=NSC(NC2=NC(C)=CN3C2=NC=C3C4=CNN=C4)=C1)CO
  • 化学全称
    1-Propanol, 2-[ethyl[[5-[[6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-isothiazolyl]methyl]amino]-2-methyl-

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Yu T, et al. ACS Med Chem Lett. 2010 Jun 7;1(5):214-8. 2. Basso AD, et al. Cancer Chemother Pharmacol. 2011 Oct;68(4):923-33.
产品手册
关联产品
  • PHA-680632

    一种有效的、高选择性的 Aurora 激酶抑制剂,对 Aurora A、B 和 C 的 IC50 值分别为 27、135 和 120 nM。

  • Pilaralisib

    Pilaralisib 是一种口服小分子,可选择性抑制磷酸肌醇 3 激酶 (PI3K) 的活性。

  • Ilorasertib hydrochl...

    Ilorasertib (ABT-348) hydrochloride 是一种有效的,具有口服活性和 ATP 竞争性的 aurora 抑制剂,对 aurora A, aurora B, aurora C 的 IC50 值分别为 116, 5, 1 nM。Ilorasertib hydrochloride 也是一种有效的 VEGF 和 PDGF 抑制剂。Ilorasertib hydrochloride 具有用于急性髓系白血病 (AML) 和骨髓增生异常综合征 (MDS) 的研究潜力。